IRLAB TherapeuticsCompany research
Click on headlines below to download research
Executive interview
IRLAB Therapeutics – executive interview (26 July 2024) | 26/07/2024
IRLAB Therapeutics (IRLAB-A) is a Sweden-based biotechnology company focused on developing novel drugs for the treatment of neurodegenerative diseases,…
Anticipation builds as inflection points approach
IRLAB Therapeutics | 11/07/2024
IRLAB continued to progress its pipeline in Q224 and met key milestones, such as the clinical entry of IRL757 with non-dilutive backing from the Michael…
Pirepemat passes Phase IIb DSMB safety hurdle
IRLAB Therapeutics | 03/07/2024
IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and data integrity reviews for its ongoing Phase IIb clinical…